Targeted Axillary Lymph Node Dissection after Neoadjuvant Treatment of Breast Cancer Using Indocyanine Green Compared to Patent Blue V Dye | ||
| The Egyptian Journal of Surgery | ||
| Article 14, Volume 44, Issue 3, July 2025, Pages 908-916 PDF (414.13 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ejsur.2024.344921.1317 | ||
| Authors | ||
| Ahmed Mahmoud Abdelsalam Ali* ; Usama Mohamed Abdalla Elattar; Amr Arafa Mohammed Abdel-Alim; Karim Fahmy Abd Elmoaty | ||
| Department of General Surgery, Faculty of Medicine, Ain Shams University, Egypt. | ||
| Abstract | ||
| Background: For patients with breast cancer, targeted axillary lymph node dissection (TAD) after neoadjuvant therapy is an essential surgery for precise axillary staging. TAD with sentinel lymph node (SLN) detection may be enhanced by using indocyanine green (ICG), a promising substitute for conventional dyes. The effectiveness of ICG and patent blue V dye (PBVD) in identifying targeted axillary LNs and SLNs during axillary dissection in patients with breast cancer following neoadjuvant treatment is being compared in this prospective randomized controlled experiment. As a result, there will be less need for a full axillary LN dissection and fewer side effects. Patients and Methods: This study was conducted at Ain Shams University Hospitals between October 2022 and March 2024. A total of 60 breast cancer patients received neoadjuvant therapy and were prepared for surgery of TAD. They were randomized in a 1:1 ratio using randomization software (random.org) into two groups: group A underwent TAD using ICG dye and group B underwent TAD using PBVD. The primary endpoint was the targeted LN, as well as the SLNs removed detection rate, number, and accuracy. Results: The study examined variations in the two groups’ SLN detection rates, the quantity of SLNs found, and their adverse consequences. In comparison to PBVD, ICG is said to have shown better SLN detection and identification, as well as fewer problems and adverse effects. Conclusion: The purpose of this experiment is to determine if ICG provides a more accurate and dependable technique for both targeted LN and SLN detection in patients with breast cancer who have received neoadjuvant treatment. By increasing nodal staging accuracy and lowering the possibility of missing sentinel nodes, the data could validate ICG as the preferred tracer for TAD. | ||
| Keywords | ||
| Indocyanine green; Neoadjuvant therapy; Patent Blue V Dye; Sentinel lymph node; Targeted axillary lymph node dissection | ||
|
Statistics Article View: 28 PDF Download: 20 |
||
